RxDoctor Payments Data

Varun Vijay, MD

Urology · Morristown, NJNPI 1710475256

Payments from drug & device makers

$4,470in general payments, 2019–2025

Across 102 payments — averaging $43.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Coloplast$305
  • Antares Pharma, Inc.$250
  • Calyxo, Inc.$209
  • Olympus America Inc.$170
  • Ferring Pharmaceuticals Inc.$158
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1,22527%
  • Food & beverage$3,24573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,470 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$338,837
Medicare patients
837
Services billed
5,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron56$52,241
MyrbetriqMirabegron55$50,203
Tamsulosin Hcl325$6,245
Finasteride137$2,784
Oxybutynin Chloride ErOxybutynin Chloride48$1,719
Testosterone Cypionate39$1,598
Testosterone12$1,133
Estradiol19$1,047
Solifenacin Succinate19$992
Tolterodine Tartrate ErTolterodine Tartrate14$877
Cefpodoxime Proxetil20$705
Alfuzosin Hcl ErAlfuzosin Hcl24$549
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$218
Insulin SyringeSyringe And Needle,insulin,1ml23$196
Clotrimazole12$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$141$52,24156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.

Other urology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →